AbbVie will provide low prices in Medicaid, and expand affordable, direct-to-patient offerings for treatments used by millions of Americans through TrumpRx

AbbVie announced a voluntary agreement with the Trump administration to further advance access and affordability for Americans while protecting and investing in U.S. pharmaceutical innovation.

Health Technology Insights: MHK Launches SmartProminence AI Solutions

The company will provide low prices in Medicaid while pledging $100 billion in U.S.-based research and development and capital investments, including manufacturing, over the next decade. AbbVie will also expand direct-to-patient offerings through TrumpRx for medicines used by millions of Americans, including ALPHAGAN, COMBIGAN, HUMIRA and SYNTHROID.

Health Technology Insights: Artera Secures $65Million Growth Investment and Reaches $100Million CARR

“AbbVie’s mission is to make a remarkable impact for the patients we serve around the world through our innovative medicines,” said Robert A. Michael, chairman and chief executive officer, AbbVie. “With approximately 29,000 U.S.-based employees and products treating 16 million Americans annually, we understand the complexity and access challenges in our healthcare system. AbbVie is following President Trump’s call to action by reaching this agreement, allowing us to collectively move beyond policies that harm American innovation. Thank you to President Trump and his team for their leadership to help deliver cost savings and supporting our efforts to deliver innovative treatments for American patients.”

AbbVie’s agreement, which addresses all four of the President’s drug pricing priorities, was enabled by the Trump administration providing exemption from tariffs and future price mandates, and the government’s continued efforts to ensure global prices reflect the full value of U.S. medical innovation. Further terms of this agreement remain confidential.

Health Technology Insights: First Stop Health Joins ParetoHealth Network

To participate in our interviews, please write to our HealthTech Media Room at info@intentamplify.com